Skip to content
OpenCapital
Get started

Charles River Laboratories CRL Unpaid advanced client billings

Other financials

Income statement

See full
Revenue$995.8M+1.2%
Gross profit$349.0M-3.5%
Operating income$119.9M+60.6%
Net income-$14.8M-158%
EPS (diluted)-$0.30-160%

Balance sheet

See full
Cash & equivalents$198.2M-14.5%
Total debt$3.1B+1.9%
Total equity$2.9B-7.9%
Total assets$7.7B+2.0%

Cash flow

See full
Operating cash flow$41.1M-76.1%
CapEx$55.9M-5.8%
Free cash flow-$14.8M-113%

Valuation

See full
Market cap$8.91B+10.3%
Enterprise value$11.79B+8.5%
P/S2.2×+0.2×

Profitability

See full
Gross margin84.7%—
Operating margin13%-2.4pp
Net margin-4.6%—
FCF margin9.7%-4.3pp

Returns & leverage

See full
Return on equity-6%—
Debt / equity1×+0.1×
Current ratio1.4×-0.1×

Where this comes from

Reported directly by Charles River Laboratories in its filing.

Tagged under the XBRL concept crl:ContractWithCustomerUnpaidAdvancedClientBillings.

The official record: Charles River Laboratories’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Charles River Laboratories's unpaid advanced client billings.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Charles River Laboratories's unpaid advanced client billings?
Charles River Laboratories (CRL) reported unpaid advanced client billings of $44M in Q1 2026.
How has Charles River Laboratories's unpaid advanced client billings changed year-over-year?
Charles River Laboratories's unpaid advanced client billings increased by 12.8% year-over-year, from $39M to $44M.
What is the long-term trend for Charles River Laboratories's unpaid advanced client billings?
Over 5 years (2020 to 2025), Charles River Laboratories's unpaid advanced client billings has grown at a 21.9% compound annual growth rate (CAGR), from $16M to $43M.